Table 2. Frequencies of autoimmune rheumatic diseases (ARD) and current patients’ therapy.
| ARD | N = 159 (%) | |
|---|---|---|
| Systemic lupus erythematosus/cutaneous lupus | 65/2 (40.8/1.3) | |
| Chronic inflammatory arthritis (RA, AS, PsA, JIA) | 31 (19.5) | |
| Other autoimmune disease (pSS, DM/PM, MCTD) | 18 (11.3) | |
| Systemic sclerosis | 16 (10.1) | |
| Primary antiphospholipid syndrome | 15 (9.4) | |
| Primary systemic vasculitis (BD, TA, GPA) | 12 (7.5) | |
| CURRENT THERAPY ARD patients under IS/IM–n(%) Total 106/159 (66.6) | Only one IS/IM–n(%) 83/106 (78.3) | Association of IS/IM–n(%) 23/106 (21.7) |
| Hydroxychloroquine 66 (41.5) | 46 (28.9) | 20 (12.6) |
| Prednisone 25 (15.7) | 10 (6.3) | 15 (9.4) |
| Methotrexate 24 (15.1) | 15 (9.4) | 8 (5.0) |
| Leflunomide 14 (8.8) | 9 (5.7) | 5 (3.1) |
| Sulfasalazine 6 (3.8) | 3 (1.9) | 3 (1.8) |
RA—rheumatoid arthritis, AS–ankilosing spondilitis, PsA–psoriatic arthritis, JIA- juvenile idiopatic arthritis, pSS–primary Sjögren syndrome, DM/PM–dermatomyositis/polymyositis, MCTD–mixed connective tissue disease, BD- Behçet’s disease, TA-Takayasu’s arteritis, GPA—Granulomatosis with polyangiitis, IS- imunossupressive agent, IM–immunomodulator agent